Tarlatamab (Imdelltra) is a new type of immunotherapy approved for people with small-cell lung cancer whose disease has ...

This is the first trial combining Allarity’s stenoparib with another anti-cancer agentStenoparib’s favorable safety profile supports ...

Frontline: Surgery to remove the tumor is often considered, sometimes followed by chemotherapy or radiation to reduce ...

The therapeutic landscape of small cell lung cancer (SCLC) is undergoing a paradigm shift with the emergence of delta-like ligand-3 (DLL3)–directed therapies, particularly tarlatamab, a first-in-class ...

Is Zepzelca Right for Me? To help choose the right treatment for you, your health care provider will consider what type of lung cancer you have, the treatments you have received, and whether the ...

Small cell lung cancer (SCLC) is one of the most aggressive forms of lung cancer, with a five-year survival rate of only 5%. Despite this poor prognosis, SCLC is initially highly responsive to ...

Key opportunities in the Global Small Cell Lung Cancer Therapeutics Market include the growing demand for advanced ...

Filippo Beleggia, MD, PhD, didn’t believe his own data. As a postdoctoral researcher, he spent years in the laboratory of Christian Reinhardt, MD, PhD, at the University Hospital Cologne, Cologne, ...